Mark Stein, PhD, ABPP

Personal Statement

I am a Profesor of Psychiatry, Adjunct Professor of  Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s and Seattle Children’s at Overlake Hospital in Bellevue. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s and schools. The majority of my clinical work involves  diagnostic evaluations and consultations. Treatment recommendations are made for the parents, referring physician, and schools. I also direct the clinical program for SEA STAR, a summer treatment program for children with ADHD and related disorders that targets social impairment and self-esteem, in collaboration with the UW Autism Center.

Comparative efficacy and personalized ADHD treatment are major themes of my work. I have published over 120 articles, mostly having to do with ADHD diagnosis and treatment in all ages, and specific areas within ADHD such as genetics, thyroid, and sleep . I have  participated in numerous clinical trials of stimulant  and non stimulant medications. Current research studies involve parents with ADHD, children with ADHD and Autism, and a new NIH sponsored study examining the effects of abruptly discontinuing methylphenidate in children with ADHD.

Other areas of interest include sleep problems and overlap with ADHD, pediatric psychology, and research ethics. Finally, I participate in the ITHS Treatment Innovatiopn Center, focusing on removing barriers to multi-site clinical and translational studies.

Education

Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic

Recent Publications

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
(2021 Dec)
Eur Urol Open Sci 34(): 70-78
Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI

Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
(2022 Mar)
Immunotherapy 14(4): 215-224
Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, Yel L

Home direct-to-consumer telehealth solutions for children with mental health disorders and the impact of Covid-19.
(2021 Dec 20)
Clin Child Psychol Psychiatry
Norman S, Atabaki S, Atmore K, Biddle C, DiFazio M, Felten D, Fox E, Marschall D, Newman J, Robb A, Rowland C, Selekman R, Slovin A, Stein M, Strang J, Sable C

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.
(2021 Nov)
Cancer Med 10(22): 7909-7920
Kim IE, Jang TL, Kim S, Lee DY, Kim DD, Singer EA, Ghodoussipour S, Stein MN, Aron M, Dall'Era MA, Yi Kim I

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
(2021 Oct 12)
Oncotarget 12(21): 2231
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS

Show complete publication list »
Edit Profile